Research programme: cancer therapeutics - Inception 2
Latest Information Update: 28 Jul 2016
At a glance
- Originator Inception 2
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 28 Jul 2016 Investigation in Cancer in Canada (unspecified route)
- 28 Jul 2016 Investigation in Cancer in USA (unspecified route)